Cetuximab-Associated Elongation of the Eyelashes

In 2011, a case report documented a 58-year-old African American woman with metastatic rectal carcinoma who experienced eyelash trichomegaly after starting treatment with cetuximab, an EGFR inhibitor. This condition, characterized by the elongation of the eyelashes, began within the first month of therapy and persisted for 5 months. Although the patient's cancer progressed and she eventually died, the eyelash growth was considered cosmetically enhancing, and she managed it by occasionally trimming her eyelashes. The report indicated that while eyelash trichomegaly is a rare and benign side effect of EGFR inhibitors, it can be managed by trimming and usually resolves after the cessation of the drug. No funding was used for the report, and no conflicts of interest were declared by the authors.